Table 3.
Pharmacokinetic parameters for buspirone and 1-(2-pyrimidinyl)-piperazine after either F1 or F2 administration
| Dosing | C max (ng/mL) | T max (h) | AUC(0–1,590) (ng*h/mL) | AUC extrapolated(0–∞) (ng*h/mL) | Tlag (h) | T ½ (h) |
|---|---|---|---|---|---|---|
| F1 buspirone (ng/mL) | 3.95 ± 4.38 | 3.69 ± 0.54 | 7.63 ± 8.07 | 8.02 ± 8.57 | 2.96 ± 0.14 | 6.03 ± 2.27 |
| F2 buspirone (ng/mL) | 2.16 ± 2.55 | 3.95 ± 1.82 | 5.14 ± 5.08 | 5.56 ± 5.24 | 3.33 ± 0.82 | 7.12 ± 2.33 |
| F1 1-(2-pyrimidinyl)-piperazine (ng/mL) | 4.35 ± 1.65 | 4.02 ± 0.68 | 25.4 ± 14.60 | 27.4 ± 17.8 | 3.27 ± 0.33 | 4.84 ± 2.11 |
| F2 1-(2-pyrimidinyl)-piperazine (ng/mL) | 3.99 ± 1.71 | 4.40 ± 2.27 | 21.6 ± 6.7 | 22.7 ± 7.4 | 3.58 ± 1.32 | 4.86 ± 1.66 |
The values are mean ± SD. The means of F1 are calculated with the data of 13 women and the means of F2 are based on the data of 12 women
AUC area under the curve, C max maximum concentration, Tlag absorption lag time, T max time to maximum concentration, T ½ half-life